Theoretical · Grade C
Epitalon
Epitalon (Epithalon/Epithalone)
Score
60 / 100
Origin
Pineal (Russia)
Mechanism
Telomerase activation
Status
Preclinical / Russian data
TL;DR
01
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on a pineal-gland extract, developed by Russian gerontologist Vladimir Khavinson and marketed for longevity.
02
Its headline lab finding is real: in cultured human cells it activated telomerase and lengthened telomeres — a plausible anti-aging mechanism.
03
Beyond that, the human evidence is thin and largely Russian: rodent lifespan studies and observational cohorts from Khavinson's group, without independent Western trials.
04
Telomerase activation is also double-edged — the same mechanism that could slow cellular aging is one cancers exploit, and long-term human safety is unstudied.
05
It is not approved and is sold as a research chemical with no quality guarantees.
Independent Western RCTs
None
evidence largely Russian
Telomerase (in vitro)
Activated
human fibroblast culture
Evidence source
Khavinson group
originating lab
Cancer caution
Yes
telomerase is double-edged
Approval
None
research chemical
Part 01 · How it works
Mechanism.
Epitalon is a four-amino-acid peptide modeled on a substance from the pineal gland, promoted as a longevity aid. Its most striking result is that, in cultured human cells, it switched on telomerase — the enzyme that rebuilds the protective caps on chromosomes — and lengthened those caps, which is a legitimate anti-aging mechanism on paper. The problem is the rest of the evidence: mostly rodent studies and observational human data from the same Russian group that developed it, with no independent Western trials. And activating telomerase is a two-edged sword, because runaway telomerase is a feature of cancer.
A peptide that, in a dish, tells cells to rebuild the protective caps on their DNA — a real anti-aging idea, but proven mostly by its inventor's own lab, and using the same lever cancer cells pull.
Pineal tetrapeptide
Ala-Glu-Asp-Gly, derived from the pineal extract epithalamin (Khavinson bioregulator program).
Telomerase activation
Induced telomerase catalytic subunit expression, enzymatic activity, and telomere elongation in telomerase-negative human fibroblasts.
Longevity claims
Rodent lifespan and observational human cohort data reported, largely from the originating group.
Evidence stage
In vitro + rodent + Russian observational; no independent Western RCTs.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for Epitalon. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
2 mg/day (most-documented community course); some run 5–10 mg/day
Subcutaneous injection (Russian trials of the parent peptide Epithalamin used IV) · Once daily, typically PM
Duration
20-day course repeated ~3x/year (a 5–10 mg/day × 10-day variant is also used)
·
No human trial has established an Epitalon dose; every figure is a community convention loosely anchored to Russian Epithalamin work, not internationally standardized.
·
The most widely documented protocol is 2 mg/day for 20 days, ~3x/year; the prior 5–10 mg/day reflects only the higher-dose variant.
·
Research-chemical supply carries no purity or dose guarantee.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection-site reactions
For injectable use; anecdotal.
Reported
General tolerability
In Russian reports; limited independent data.
Reported good
Serious · rare
Oncologic concern (telomerase)
Chronic telomerase activation is mechanistically linked to cancer; unstudied long-term in humans.
Theoretical
Long-term independent safety
No independent long-term human safety data.
Unknown
Product-quality risk
Research-chemical supply; purity/dose unknown.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to epitalon or any component
×
Active autoimmune disease (may modulate immune function)
×
Active malignancy (telomerase activation theoretical concern)
Relative · discuss first
!
Active or prior cancer — telomerase-activation mechanism, theoretical concern
!
Pregnancy or breastfeeding — no data
!
Anyone expecting independently validated benefit — none exists
!
Family history of cancer — weigh the telomerase mechanism carefully
Interactions
Immunosuppressants
Epitalon may modulate immune function through pineal-thymic axis; may interfere with immunosuppressive therapy
Moderate
Melatonin supplements
Epitalon stimulates endogenous melatonin production; additive effects possible
Minor
Chemotherapy agents
Theoretical concern that telomerase activation could interfere with anti-cancer mechanisms
Moderate
Labs to monitor
CBC with Differential
Baseline and every 3 months
Monitor immune and hematologic parameters
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
Melatonin Level (optional)
Baseline (optional)
Epitalon stimulates pineal melatonin production
Cortisol (AM)
Baseline and at end of cycle
Circadian rhythm modulation monitoring
Part 04 · Evidence
How strong is the evidence?
60
Grade C
Grade C, Theoretical. Epitalon has a genuine in-vitro telomerase-activation finding and a coherent longevity rationale, but the human evidence is thin, largely Russian and single-group, with no independent trials — and telomerase activation carries a real cancer caution.
Mechanistic plausibility
In-vitro telomerase activation is a real, plausible anti-aging mechanism.
72
Human evidence
Largely Russian/observational and single-group; no independent Western RCTs.
40
Safety & tolerability
Reported well tolerated, but telomerase activation raises an unstudied long-term cancer question.
55
Durability
No robust independent long-term human data.
55
Independence
Evidence concentrated in the originating (Khavinson) group.
40
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2003
Bull Exp Biol Med Flagged
Epithalon induces telomerase activity and telomere elongation in human somatic cells
Adding epitalon to telomerase-negative human fetal fibroblasts induced telomerase catalytic-subunit expression, enzymatic activity, and telomere elongation.
Human fibroblast cell culture · Foundational in-vitro result from the originating (Khavinson) group; not human interventional evidence.
PMID 12937682 ↗
Moderate (in vitro)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Evidence is largely single-group and non-Western; no independent trials
Mechanism limit international evidence base · 2003
Epitalon's longevity and telomere findings come predominantly from the originating Russian group (in-vitro, rodent, and observational human cohorts). There are no independent Western randomized trials confirming a clinical benefit.
What this means: A striking in-vitro result and inventor-led human data are a weak basis for anti-aging claims. Independent confirmation is absent.
PMID 12937682 ↗
02
Telomerase activation is a double-edged mechanism
Safety signal mechanism caution · 2003
The same telomerase activation proposed to slow cellular aging is a hallmark that cancers exploit to become immortal; the long-term oncologic safety of chronically activating telomerase in humans is unstudied.
What this means: The mechanism that makes epitalon appealing is also its clearest theoretical risk. Unmonitored long-term use is a gamble.
PMID 12937682 ↗
Part 06 · Cost & access
Where it's available, at what price.
Russia
Marketed (bioregulator)
Sold within the Khavinson 'bioregulator' framework; not an internationally approved drug.
Russian market
United States
Not approved
No approved product; research chemical.
Grey-market; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. Epitalon is marketed for longevity but has no independent Western trials; consumer supply is research-grade and unregulated, and its telomerase mechanism carries an unstudied long-term cancer caution. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
What is the quality of evidence for epitalon's telomerase activation in humans?
02
Are there safety concerns about activating telomerase, particularly regarding cancer risk?
03
How does the Russian clinical research on epitalon compare to Western evidence standards?
04
Would measuring my telomere length before and during treatment be informative?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Epithalon induces telomerase activity and telomere elongation in human somatic cells · Bull Exp Biol Med, 2003 · PMID 12937682 ↗
- 02. St. Petersburg Institute of Bioregulation and Gerontology. Khavinson epitalon/epithalamin research program